Studi Pustaka Reaksi Obat yang Merugikan pada Terapi Covid-19
Abstract
Abstract. Coronavirus Disease 2019 or Covid-19 is a new disease that can cause respiratory problems and pneumonia. This disease is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Adverse Drug Reaction (ADR) is defined as the body's response to a drug that is detrimental or dangerous and undesirable that occurs at normal doses used in humans. The aim of this literature study is to provide information to the public and researchers on Covid-19 therapy based on literature studies including the types of ADR that occur and the drugs that cause them. The data used in this research is secondary data. Secondary data is data obtained not from direct observation, but the data is obtained from the results of research conducted by previous researchers. The secondary data sources in question are in the form of literature reviews and primary or original scientific reports contained in articles or journals that have been taken from Google Scholar, Science Direct, Pubmed regarding the undesirable effects of Covid-19 drugs. Based on a study of ten articles in 2020- 2023, it is known that ADR occurred from Covid-19 therapy caused by Covid-19 therapy drugs with reactions in the form of hyperbilirubination, hyperkalemia, increased transminase, liver dysfunction, angioedema and urticaria, and a higher increase in serum creatinine.
Abstrak. Corona virus Disease 2019 atau Covid-19 adalah penyakit baru yang dapat menyebabkan gangguan pernapasan dan radang paru. Penyakit ini disebabkan oleh infeksi Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Adverse Drug Reaction (ADR) didefinisikan sebagai respon tubuh terhadap obat yang bersifat merugikan atau berbahaya dan tidak diinginkan yang terjadi pada dosis normal yang digunakan pada manusia. tujuan dari studi literatur ini adalah bahan informasi pada masyarakat dan peneliti pada terapi Covid-19 berdasarkan studi literatur mencakup jenis ADR yang terjadi dan obat penyebabnya. Data yang digunakan dalam penelitian ini adalah data sekunder. Data sekunder merupakan data yang diperoleh bukan dari pengamatan langsung, akan tetapi data tersebut diperoleh dari hasil penelitian yang dilakukan oleh peneliti-peneliti terdahulu. Sumber data sekunder yang dimaksud berupa literatur review dan laporan ilmiah primer atau asli yang terdapat di dalam artikel atau jurnal yang sudah diambil dari google scholar, science direct, pubmed berkenaan dengan efek yang tidak diinginkan pada obat Covid-19. Berdasarkan kajian dari sepuluh artikel tahun 2020-2023, diketahui bahwa terjadi ADR dari terapi Covid-19 yang disebabkan oleh obat terapi Covid-19 dengan reaksi berupa Hiperbilirubin, Hiperkalemia, Peningkatan transminase, Disfungsi hati, Angioedema dan urtikaria, dan Peningkatan kreatinin serum lebih tinggi.
References
Abdul Alim, & Jiten P. Kothadia. (2021, July 18). REMDESIVIR. Jaringan Kesehatan Lehigh Valley, Allentown, AS .
Albrecht, J Mark, Benjamin R, Jacquelyn D (2023). Nirmatrelvir-ritonivir, Covid- 19 and possible adverse skin reactions. University of California.
Budiarta Nyoman, Juanita A, Arymbhi D, Meriyani H, dan Ananda T (2020).
Penggunaan Antiviral Remdesivir untuk Pasien COVID-19 dengan Kehamilan. Universitas Mahasaraswati Denpasar.
Burhan, Erlina, dkk, (2020), Pedoman Tatalaksana Covid-19, Jakarta : Perhimpunan Dokter Paru Indonesia (PDPI).
Caroline o'Donnel , Tammie Lee Demler (2023). Assessing the use of nirmatrelvir/ritonavir and considerations regarding its drug interactions in COVID-19 positive patients at an adult inpatient state psychiatric facility . University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice, 160 Hayes Rd, Buffalo, NY 14215.
Crescioli Giada, Valentina B, Cecilia L, Andrea B, Elias R, Rinaldo I, Guido M, Alfredo M (2020). Adverse Drug Reactions in SARS-CoV-2 hospitalised patients: a case series with a focus on drug-drug interactions. Careggi University Hospital, Florence, Italy
Devaux, C.A. et al. (2020) “New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,” International Journal of Antimicrobial Agents, 55(5). doi:10.1016/j.ijantimicag.2020.105938. van Doremalen, N. et al. (2020) “Aerosol and Surface Stability of SARSCoV-2 as Compared with SARS-CoV-1,” New England Journal of Medicine, 382(16), pp. 1564–1567. doi:10.1056/nejmc2004973.
Dr. Ir. Penny Kusumastuti Lukito, MCP, 2022. Informatorium Obat COVID-19 di Indonesia edisi 4. diterbitkan oleh Badan Pengawas Obat dan Makanan Republik Indonesia.
Edward IR & Aronson JK, 2000. Adverse Drug Reactions: Definition, Diagnosis and Management. The Lancet, 356:1255-1259.
Etikasari, B. et al. (2020) ‘Sistem Informasi Deteksi Dini Covid-19’(2).
Figen, Ayperi, et al (2022). Favipiravir-induced angioedema and urticaria in COVID-19 patients. Health Sciences University Faculty of Medicine, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey.
Fransiscus kamaleera (2022). Acute Kidney Failure Injury Related to the covid drug Remdesivir. Sichuan University, Chengdu, China.
Kemenkes RI (2020) Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19), Germas.
Kemenkes RI. 2021. Profil Kesehatan Indonesia 2020. Jakarta: Kemenkes RI. Nebeker, J. R., Paul B., and Matthew H. S.. 2004. Clarifying Adverse Drug
Rosari Fransiska, I Yuda P (2020). Efek Samping Obat Antiviral Pada Pasien Covid dirumah Sakit Bali. Universitas Riau. Indonesia.
Santi Greta, Nicola M, and Domenico M (2022). Safety Profile of Molnupiravir in the Treatment of COVID-19. University of Bologna, 40126 Bologna, Italy.
Schatz, Stephanie N. dan R.J. Weber. 2015. Adverse Drug Reactions. PSAP CNS/Pharmacy Practice.
Susilo et al. 2020. Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia. Vol. 7, No.1. Jakarta.
UNICEF. Covid-19 dan Anak-anak di Indonesia. (2020).
Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia. Pedoman Tatalaksana COVID-19. PAPDI. 2020:3:56-57. Diunduh dari:
https://www.papdi.or.id/pdfs/983/Buku-Pedoman-Tatalaksana-COVID-19- 5OP-Edisi-3-2020.pdf. Pada 26 Mei 2021.
Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–7.
Vincent. 2005. ISO 9001 : 2000 And Continual Improvement. Jakarta: Gramedia Pustaka Utama.
Vinet, L., & Zhedanov, A. (2016). Konsep Pneumonia dengan Bersihan Jalan Napas Tidak efektif. Journal of Physics A: Mathematical and Theoretical, 44(8), 1689–1699.
WHO. Coronavirus Disease (COVID-19) Pandemic. World Health Organization.
Wu bin, Min L, Fengbo W, Zhiyao H, and Ting xu (2022). Acute Kidney Injury Associated With Remdesivir. University Sichuan. China.
Yin Lee J, Shoon A, Mohd N, Li min, Azzura O (2021). Incidence of Adverse Reaction of Drugs Used in COVID-19. Universitas Huddersfeld. Inggris.
Zhong, B. L., Luo, W., Li, H. M., Zhang, Q. Q., Liu, X. G., Li, W. T., & Li, Y. (2020). Knowledge, attitudes, and practices towards COVID-19 among chinese residents during the rapid rise period of the COVID-19 outbreak: A quick online cross-sectional survey. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.45221.
